TargetMol

Efipladib

Product Code:
 
TAR-T27243
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27243-5mg5mg£1,091.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27243-50mg50mg£2,143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27243-100mg100mg£2,801.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Efipladib is a phospholipase inhibitor. Efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid.
CAS:
381683-94-9
Formula:
C40H35Cl3N2O4S
Molecular Weight:
746.14
Purity:
0.98
SMILES:
OC(=O)c1ccc(CCCc2c(CCNS(=O)(=O)Cc3ccc(Cl)c(Cl)c3)n(C(c3ccccc3)c3ccccc3)c3ccc(Cl)cc23)cc1

References

1. Nickerson-Nutter CL, Goodwin D, Shen MW, Damphousse C, Duan W, Samad TA, McKew JC, Lee KL, Zaleska MM, Mollova N, Clark JD. The cPLA2? inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid. Neuropharmacology. 2011 Mar;60(4):633-41. doi: 10.1016/j.neuropharm.2010.11.025. PubMed PMID: 21146550. 2. McKew JC, Lee KL, Shen MW,et al. Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl )-1H-indol-3-yl]propyl}benzoic acid, efipladib. J Med Chem. 2008 Jun 26;51(12):3388-413. doi: 10.1021/jm701467e. PubMed PMID: 18498150. 3. Yao M, Xie C, Kiang MY, Teng Y, Harman D, Tiffen J, Wang Q, Sved P, Bao S, Witting P, Holst J, Dong Q. Targeting of cytosolic phospholipase A2? impedes cell cycle re-entry of quiescent prostate cancer cells. Oncotarget. 2015 Oct 27;6(33):34458-74. doi: 10.18632/oncotarget.5277. PubMed PMID: 26416244; PubMed Central PMCID: PMC4741466. 4. Niknami M, Vignarajan S, Yao M, Hua S, Witting PK, Kita Y, Shimizu T, Sved P, Patel MI, Dong Q. Decrease in expression or activity of cytosolic phospholipase A2alpha increases cyclooxygenase-1 action: A cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells. Biochim Biophys Acta. 2010 Jul;1801(7):731-7. doi: 10.1016/j.bbalip.2010.03.003. PubMed PMID: 20227521.